Efficacy of emetic and United State pharmacopoeia ipecac syrup in prevention of drug absorption.
The efficacy of both the emetic syrup prepared in the previous report and the United States Pharmacopoeia (USP) ipecac syrup concerning the prevention of drug absorption was investigated in 4 beagle dogs using a randomized and cross-over design. In order to control the intragastric pH of the beagle dogs, the administration of pentagastrin or hydrochloric acid (HCl)-glycine buffer (pH 1.5) was tested. The intragastric pH changed from 7.2 to 1.8 with the intramuscular administration of pentagastrin, but the primary emesis occurred more slowly. On the other hand, the HCl-glycine buffer (pH 1.5) gave the appropriate emesis. Therefore, the HCl-glycine buffer (pH 1.5) was used to control the intragastric pH of the beagle dogs. Acetaminophen (AcA), salicylic acid (SA) and kanamycin (KM) as markers were administered orally after conditioning the intragastric pH at 1.5. The emetic syrup or the USP ipecac syrup was then administered. The recovery rate of AcA and KM from vomit was 42-65%. The emetic syrup and the USP ipecac syrup significantly reduced the absorption of AcA from the calculation of pharmacokinetic parameters compared to the control syrup. It was observed that the absorption of cephaeline (CP) in the emetic syrup was less than that of CP in the USP ipecac syrup.
Teshima
D
D
Department of Hospital Pharmacy, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Suzuki
A
A
Otsubo
K
K
Higuchi
S
S
Aoyama
T
T
Shimozono
Y
Y
Saita
M
M
Noda
K
K
D000042:Absorption; D000818:Animals; D004285:Dogs; D004639:Emetics / Q000627:therapeutic use*; D004640:Emetine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007486:Ipecac / Q000627:therapeutic use*; D008297:Male; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D011041:Poisoning / Q000517:prevention & control*; D011897:Random Allocation
D004639:Emetics; D004364:Pharmaceutical Preparations; D007486:Ipecac; C005963:cephaelin; D004640:Emetine